Prefer Newsweek on Google to see more of our trusted coverage when you search. Neal Browning, one of the first people to test the COVID-19 Moderna mRNA vaccine, has taken to social media six years ...

The Advisory Committee on Immunization Practices’ COVID-19 Immunization Workgroup has proposed three federal actions to address post-acute COVID-19 vaccination syndrome, or PACVS, a condition ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...

Just over two months into 2026, Moderna has weathered a number of regulatory and financial storms that could have proven catastrophic. Moderna, which was already financially struggling, announced ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology ...

March 4 (Reuters) - Moderna shares rose ⁠9% ⁠on Wednesday after it settled ⁠a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing ...

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...

Moderna said it settled patent lawsuits over its blockbuster COVID-19 vaccine for $950 million, with another $1.3 billion payout possible depending on the outcome of a federal appeal. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The settlement could go as high ...